Valuation Update With 7 Day Price Move • May 08
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩16,020, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 77% over the past three years. New Risk • May 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Mar 20
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₩19,340, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 137% over the past three years. Annonce • Feb 24
High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026 High Tech Pharm Co., Ltd., Annual General Meeting, Mar 20, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 28, daegeum-ro, eumseong-gun, chungcheongbuk-do, South Korea Valuation Update With 7 Day Price Move • Feb 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩13,900, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years. Buy Or Sell Opportunity • Jul 09
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 6.4% to ₩12,960. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Buy Or Sell Opportunity • Jun 18
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 19% to ₩12,970. The fair value is estimated to be ₩16,323, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. New Risk • Apr 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩144.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Annonce • Feb 25
High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025 High Tech Pharm Co., Ltd., Annual General Meeting, Mar 21, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 286, daegeum-ro, eumseong-gun, chungcheongbuk-do, chungju South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩66.67 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 18 April 2025. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.1%). New Risk • Dec 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩142.8b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 14
Third quarter 2024 earnings released: EPS: ₩223 (vs ₩126 in 3Q 2023) Third quarter 2024 results: EPS: ₩223 (up from ₩126 in 3Q 2023). Revenue: ₩16.9b (down 10% from 3Q 2023). Net income: ₩2.37b (up 77% from 3Q 2023). Profit margin: 14% (up from 7.1% in 3Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Sep 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to ₩13,030. The fair value is estimated to be ₩16,394, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Meanwhile, the company has become profitable. Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩16,030, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 56% over the past three years. New Risk • Jun 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩15,130, the stock trades at a trailing P/E ratio of 13.9x. Average trailing P/E is 18x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩12,200, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 5.8% over the past three years. Upcoming Dividend • Dec 20
Inaugural dividend of ₩70.00 per share Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 19 April 2024. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 1.1%. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩16,440, the stock trades at a trailing P/E ratio of 14.7x. Average trailing P/E is 16x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 13% over the past three years. Upcoming Dividend • Dec 21
Upcoming dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (1.0%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Inaugural dividend of ₩50.00 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 20 April 2022. The company is not currently making a profit and is not cash flow positive. This is the first dividend for High Tech Pharm since going public. The average dividend yield among industry peers is 0.8%. Reported Earnings • Nov 05
Third quarter 2021 earnings released: ₩8.00 loss per share (vs ₩89.00 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: ₩15.3b (down 29% from 3Q 2020). Net loss: ₩55.7m (down 109% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 4% per year, which means it has not declined as severely as earnings. Reported Earnings • May 18
First quarter 2021 earnings released: EPS ₩64.00 (vs ₩7.00 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: ₩19.6b (up 35% from 1Q 2020). Net income: ₩454.8m (up ₩498.0m from 1Q 2020). Profit margin: 2.3% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Jan 14
New 90-day high: ₩26,350 The company is up 118% from its price of ₩12,100 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 22
New 90-day high: ₩20,150 The company is up 63% from its price of ₩12,400 on 23 September 2020. The South Korean market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 07
New 90-day high: ₩15,200 The company is up 27% from its price of ₩11,950 on 08 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 5.0% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: EPS ₩89.00 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2020 results: Revenue: ₩21.5b (down 4.5% from 3Q 2019). Net income: ₩630.6m (up ₩1.71b from 3Q 2019). Profit margin: 2.9% (up from net loss in 3Q 2019). The move to profitability was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 110% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.